Serum beta2-microglobulin in malignant lymphoproliferative disorders

L. Melillo, P. Musto, P. Tomasi, N. Cascavilla, C. Bodenizza, S. Ladogana, M. Carotenuto

Research output: Contribution to journalArticlepeer-review

Abstract

Beta2-microglobulin (B2m) was measured on serum samples in 274 patients with acute and chronic lymhoproliferative disorders (85 non-Hodgkin lymphomas - NHL, 30 Hodgkin lymphomas - HL, 34 B-cell chronic lymphocytic leukemias - B-CLL, 8 Waldenstrom macroglobulinemias - WM, 76 multiple myelomas - MM, 31 acute lymphoblastic leukemias - ALL, 10 hairy cell leukemias - HCL). Two hundred and four patients were studied at the time of diagnosis, and results were correlated to clinical stage, and histologic subtype in NHL, immunoglobulin type in MM, and immunologic phenotype in ALL. Moreover, B2m was tested during and after chemo- and/or radiotherapy, and results were correlated to response, progression or relapse. Elevated pretreatment B2m values were found in widespread forms of NHL and HL, in patients with B symptoms and in the unfavorable histologic subgroups of NHL. Rapid falls in levels followed therapy institution. In B-CLL and in MM a close relationship between B2m and cell mass was found. A significant B2m level reduction followed treatment, whereas its increase could detect a relapse. In ALL, serum B2m was only slightly above the normal range. B2m seems to reflect the total burden of malignant cells mainly in MM and B-CLL; in other lymphoproliferative disorders it provides less prognostic information.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalTumori
Volume74
Issue number2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Serum beta2-microglobulin in malignant lymphoproliferative disorders'. Together they form a unique fingerprint.

Cite this